The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Dexcom Inc’s stock clocked out at $69.7, down -0.78% from its previous closing price of $70.25. In other words, the price has decreased by -$0.78 from its previous closing price. On the day, 5.84 million shares were traded. DXCM stock price reached its highest trading level at $71.28 during the session, while it also had its lowest trading level at $68.71.
Ratios:
To gain a deeper understanding of DXCM’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.60. For the most recent quarter (mrq), Quick Ratio is recorded 1.38 and its Current Ratio is at 1.56. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.49.
On December 02, 2025, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $75.
On November 25, 2025, Evercore ISI started tracking the stock assigning a In-line rating and target price of $68.Evercore ISI initiated its In-line rating on November 25, 2025, with a $68 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 14 ’25 when Collins Richard Alexander sold 2,906 shares for $59.05 per share. The transaction valued at 171,599 led to the insider holds 35,088 shares of the business.
Collins Richard Alexander bought 2,906 shares of DXCM for $171,599 on Nov 14 ’25. On Nov 12 ’25, another insider, Heller Bridgette P, who serves as the Director of the company, sold 1,012 shares for $58.07 each. As a result, the insider received 58,767 and left with 27,031 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 27333220352 and an Enterprise Value of 26437634048. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 38.79, and their Forward P/E ratio for the next fiscal year is 28.25. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.02 while its Price-to-Book (P/B) ratio in mrq is 9.97. Its current Enterprise Value per Revenue stands at 5.854 whereas that against EBITDA is 25.866.
Stock Price History:
The Beta on a monthly basis for DXCM is 1.49, which has changed by -0.17197078 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, DXCM has reached a high of $93.25, while it has fallen to a 52-week low of $54.11. The 50-Day Moving Average of the stock is 8.53%, while the 200-Day Moving Average is calculated to be -5.50%.
Shares Statistics:
It appears that DXCM traded 6.04M shares on average per day over the past three months and 5347950 shares per day over the past ten days. A total of 390.00M shares are outstanding, with a floating share count of 384.35M. Insiders hold about 1.45% of the company’s shares, while institutions hold 96.20% stake in the company. Shares short for DXCM as of 1767139200 were 14420388 with a Short Ratio of 2.39, compared to 1764288000 on 13046267. Therefore, it implies a Short% of Shares Outstanding of 14420388 and a Short% of Float of 4.75.
Earnings Estimates
. The current rating of Dexcom Inc (DXCM) is the result of assessments by 23.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.48, with high estimates of $0.55 and low estimates of $0.4.
Analysts are recommending an EPS of between $2.17 and $1.96 for the fiscal current year, implying an average EPS of $2.06. EPS for the following year is $2.47, with 26.0 analysts recommending between $2.68 and $2.29.
Revenue Estimates
In. The current quarter, 16 analysts expect revenue to total $1.25B. It ranges from a high estimate of $1.26B to a low estimate of $1.24B. As of. The current estimate, Dexcom Inc’s year-ago sales were $1.11BFor the next quarter, 16 analysts are estimating revenue of $1.18B. There is a high estimate of $1.26B for the next quarter, whereas the lowest estimate is $1.13B.
A total of 19 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.66B, while the lowest revenue estimate was $4.64B, resulting in an average revenue estimate of $4.65B. In the same quarter a year ago, actual revenue was $4.03BBased on 22 analysts’ estimates, the company’s revenue will be $5.22B in the next fiscal year. The high estimate is $5.28B and the low estimate is $5.18B.
